Phase II trial of oral aminopterin for adults and children with refractory acute leukemia

Clinical Cancer Research

Volumn 11, Issue 22, 2005, Pages 8089-8096

  Cole, Peter D ^a,b   Drachtman, Richard A ^a,b   Smith, Angela K ^a   Cate, Sarah ^b   Larson, Richard A ^c   Hawkins, Douglas S ^d   Holcenberg, John ^d   Kelly, Kara ^e   Kamen, Barton A ^a,b  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^e Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPTERIN; ANTIFOLYLPOLYGLUTAMATE; FOLINIC ACID; METHOTREXATE; POLYGLUTAMIC ACID; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CELL METABOLISM; CELL SPECIFICITY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; FEMALE; HUMAN; IN VITRO STUDY; MALE; MUCOSA INFLAMMATION; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELIABILITY;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AMINOPTERIN; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLIC ACID ANTAGONISTS; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 28144463215     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0355     Document Type: Article

References (50)

1. Farber S, Diamond L, Mercer RD, Sylvester RF, Jr., Wolff JA. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (aminopterin). N Engl J Med 1948;238:787.
2. Burchenal JH, Burchenal JR, Kushida MW, Johnston SF, Williams BS. Studies on the chemotherapy of leukemia. Cancer 1949;2:113-8.
3. Schoenbach EB, Colsky J, Greenspan EM. Observations on the effects of the folic acid antagonists, aminopterin and amethopterin, in patients with advanced neoplasms. Cancer 1952;5:1201-20.
4. Farber S, Toch R, Sears EM, Pinkel D. Advances in chemotherapy of cancer in man. In: Greenstein HA, editor. Advances in cancer research. New York: Academic Press; 1956. p. 2-73.
5. Dacie JV, Dresner E, Mollin DL, White JC. Aminopterin in the treatment of acute leukemia. Br Med J 1950;1:1447-57.
6. Sacks MS, Bradford GT, Schoenbach EB. The response of acute leukemia to the administration of the folic acid antagonists, aminopterin and amethopterin: report of 14 cases. Ann Intern Med 1950;32:80-115.
7. Goldin A, Venditti JM, Humphreys SR, Dennis D, Mantel N. A quantitative comparison of the antileukemic effectiveness of two folic acid antagonists in mice. J Natl Cancer Inst 1955;15:1657-64.
8. Glode LM, Pitman SW, Ensminger WD, Rosowsky A, Papathanasopoulos N, Frei E, III. A phase 1 study of high doses of aminopterin with leucovorin rescue in patients with advanced metastatic tumors. Cancer Res 1979;39:3707-14.
9. Meyer LM, Fink H, Sawitsky A, Rowen M, Ritz ND. Aminopterin (a folic acid antagonist) in the treatment of leukemia. Am J Clin Pathol 1949;19:119-26.
10. Mills SD, Stickney JM, Hadedorn AB. Observations on acute leukemia in children treated with 4-aminopteroylglutamic acid. Pediatrics 1950;5:52-6.
11. Dameshek W, Freedman MH, Steinberg L. Folic acid antagonists in the treatment of acute and subacute leukemia. Blood 1950;5:898-915.
12. Meyer LM, Newman A. Treatment of leukemia with aminopterin. Am J Med 1951;10:452-8.
13. Bertino JR. Karnofsky memorial lecture. Ode to methotrexate. J Clin Oncol 1993;11:5-14.
14. Smith A, Hum M, Winick NJ, Kamen BA. A case for the use of aminopterin in treatment of patients with leukemia based on metabolic studies of blasts in vitro. Clin Cancer Res 1996;2:69-73.
15. Ratliff AF, Wilson J, Hum M, et al. Phase I and pharmacokinetic trial of aminopterin in patients with refractory malignancies. J Clin Oncol 1998;16:1458-64.
16. Balis FM, Savitch JL, Bleyer WA. Pharmacokinetics of oral methotrexate in children. Cancer Res 1983;43:2342-5.
17. Kearney PJ, Light PA, Preece A, Mott MG. Unpredictable serum levels after oral methotrexate in children with acute lymphoblastic leukaemia. Cancer Chemother Pharmacol 1979;3:117-20.
18. Winick N, ShusterJJ, Bowman WP, et al. Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukemia. J Clin Oncol 1996;14:2803-11.
19. Mahoney DH, Jr., Shuster J, Nitschke R, et al. Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group phase III trial.[see comment]. J Clin Oncol 1998;16:246-54.
20. Piper JR, Montgomery JA. A convenient synthesis of aminopterin and homologues via 6-(bromethyl)-2, 4-disminopteridine hydrobromide. J Heterocyclic Chem 1974;11:279-80.
21. Yamamoto J, Horie T, Awazu S. Amelioration of methotrexate-induced malabsorption by vitamin A. Cancer Chemother Pharmacol 1997;39:239-44.
22. Jacques PF, Selhub J, Bostom AG, Wilson PW, Rosenberg IH. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 1999;340:1449-54.
23. Magill E, Smith AK, Kamen BA. Effects of food supplementation and education on folate stores. Pediatr Hematol Oncol 2000;17:605-6.
24. Kamen BA, Takach PL, Vatev R, Caston JD. A rapid, radiochemical-ligand binding assay for methotrexate. Anal Biochem 1976;70:54-63.
25. Kamen BA, Winick N. Analysis of methotrexate polyglutamate derivatives in vivo. Methods Enzymol 1986;122:339-46.
26. Masson E, Relling MV, Synold TW, et al. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. J Clin Invest 1996;97:73-80.
27. Whitehead VM, Rosenblatt DS, Vuchich MJ, Shuster JJ, Witte A, Beaulieu D. Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts at diagnosis of childhood acute lymphoblastic leukemia: a pilot prognostic factor analysis. Blood 1990;76:44-9.
28. Goker E, Lin JT, Trippett T, et al. Decreased polyglutamylation of methotrexate in acute lymphoblastic leukemia blasts in adults compared to children with this disease. Leukemia 1993;7:1000-4.
29. Rots MG, Pieters R, Peters GJ, et al. Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia. Blood 1999;93:1677-83.
30. Lin JT, Tong WP, Trippett TM, et al. Basis for natural resistance to methotrexate in human acute non-lymphocytic leukemia. Leuk Res 1991;15:1191-6.
31. Goldin A, Greenspan EM, Schoenbach EB. Studies on the mechanism of action of chemotherapeutic agents in cancer: VI. Synergistic (additive) action of drugs on a transplantable leukemia in mice. Cancer 1952;5:153-60.
32. Heinrich MR, Dewey VC, Kidder GW. Ion-exchange chromatography of pteroylglutamic acid and aminopterin. J Am Chem Soc 1953;75:5425-6.
33. Loo TL. The purification of aminopterin. J Med Chem 1965;8:139.
34. Gorlick R, Cole P, Banerjee D, et al. Mechanisms of methotrexate resistance in acute leukemia. Decreased transport and polyglutamylation. Adv Exp Med Biol 1999;457:543-50.
35. Gorlick R, Goker E, Trippett T, Waltham M, Banerjee D, Bertino JR. Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med 1996;335:1041-8.
36. Moran RG, Colman PD, Rosowsky A, Forsch RA, Chan KK. Structural features of 4-amino antifolates required for substrate activity with mammalian folylpolyglutamate synthetase. Mol Pharmacol 1985;27:156-66.
37. Schoo MM, Pristupa ZB, Vickers PJ, Scrimgeour KG. Folate analogues as substrates of mammalian folylpolyglutamate synthetase. Cancer Res 1985;45:3034-41.
38. George S, Cichowicz DJ, Shane B. Mammalian folylpoly-γ-glutamate synthetase. 3. Specificity for folate analogues. Biochemistry 1987;26:522-9.
39. Teresi ME, Crom WR, Choi KE, Mirro J, Evans WE. Methotrexate bioavailability after oral and intramuscular administration in children. J Pediatr 1987;110:788-92.
40. Kuehl M, Brixner DI, Broom AD, Avery TL, Blakley RL. Cytotoxicity, uptake, polyglutamate formation, and antileukemic effects of 8-deaza analogues of methotrexate and aminopterin in mice. Cancer Res 1988;48:1481-8.
41. Samuels LL, Moccio DM, Sirotnak FM. Similar differential for total polyglutamylation and cytotoxicity among various folate analogues in human and murine tumor cells in vitro. Cancer Res 1985;45:1488-95.
42. Barredo JC, Synold TW, Laver J, et al. Differences in constitutive and post-methotrexate folylpolyglutamate synthetase activity in B-lineage and T-lineage leukemia. Blood 1994;84:564-9.
43. Galpin AJ, Schuetz JD, Masson E, et al. Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity. Mol Pharmacol 1997;52:155-63.
44. Longo GS, Gorlick R, Tong WP, Ercikan E, Bertino JR. Disparate affinities of antifolates for folylpolyglutamate synthetase from human leukemia cells. Blood 1997;90:1241-5.
45. Balinska M, Galivan J, Coward JK. Efflux of methotrexate and its polyglutamate derivatives from hepatic cells in vitro. Cancer Res 1981;41:2751-6.
46. 5 to dihydrofolate reductase. J Clin Invest 1983;72:773-8.
47. Rosenblatt DS, Whitehead VM. Methotrexate polyglutamates in cultured human cells. Adv Exp Med Biol 1983;163:275-85.
48. Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD. Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRPI: effect of polyglutamylation on MTX transport. Cancer Res 2001;61:7225-32.
49. Chen ZS, Lee K, Walther S, et al. Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res 2002;62:3144-50.
50. Cole PD, Drachtman RA, Masterson M, et al. Aminopterin can replace methotrexate for children with newly diagnosed acute lymphoblastic leukemia without excessive toxicity. [Abstract #1950]. Blood 2004;104:538a.